{"product_id":"non-calcified-coronary-artery-plaque-on-ct-angiograms-what-it-is-how-common-it-is-and-why-it-matters-for-your-heart","title":"Non-Calcified Coronary Artery Plaque on CT Angiograms: What It Is, How Common It Is, and Why It Matters for Your Heart","description":"\u003cp\u003eCoronary computed tomography angiography (CCTA) has emerged as a powerful tool to detect not only blockages but also the very earliest signs of heart disease—particularly non-calcified plaque (NCP), the soft, fatty buildup in artery walls that can rupture unpredictably. This comprehensive review of the medical literature found that NCP is the initial precursor of calcified plaque and serves as a prominent marker of early coronary atherosclerosis, frequently appearing in patients with zero calcium scores and in younger individuals. Notably, studies show that patients with non-calcified plaque face significantly higher risks of future heart attacks—with hazard ratios ranging from 1.6 to over 151 depending on plaque characteristics—meaning that early detection through CCTA could enable preventive measures capable of altering the course of heart disease and lowering cardiovascular events.\u003c\/p\u003e\n\u003ch1\u003eNon-Calcified Coronary Artery Plaque on CT Angiograms: What It Is, How Common It Is, and Why It Matters for Your Heart\u003c\/h1\u003e\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding the Basics: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-is-ncp\"\u003eWhat Is Non-Calcified Plaque?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#symptomatic-findings\"\u003eKey Findings: Non-Calcified Plaque in Patients with Symptoms\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#asymptomatic-findings\"\u003eKey Findings: Non-Calcified Plaque in People Without Symptoms\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eNon-calcified plaque is soft, fatty buildup that can rupture and cause heart attacks, even when calcium score is zero.\u003c\/li\u003e\n\u003cli\u003eCCTA with contrast dye detects non-calcified plaque, unlike standard calcium-scoring CT scans.\u003c\/li\u003e\n\u003cli\u003eIn studies, patients with non-calcified plaque had hazard ratios from 1.6 to 151 for heart events.\u003c\/li\u003e\n\u003cli\u003eHigh-risk plaque features like positive remodeling and low-attenuation plaque greatly increase risk.\u003c\/li\u003e\n\u003cli\u003eDiabetic patients, even young ones with zero calcium scores, often have substantial non-calcified plaque.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\u003ch2 id=\"background\"\u003eUnderstanding the Basics: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eCoronary artery disease is widely recognized as a leading cause of death in developed countries. For decades, doctors have used a simple measurement—the coronary artery calcium (CAC) score—to predict cardiovascular outcomes in people without symptoms. This test detects calcified (hardened) plaque on a non-contrast CT scan.\u003c\/p\u003e\n\u003cp\u003eBut there is a catch. Calcium is only visible once plaque has been present for a long time. Before plaque becomes calcified, it exists as \"non-calcified plaque\" (NCP)—a soft, fatty substance that is invisible to traditional calcium-scoring scans. This is where newer technology changes the picture.\u003c\/p\u003e\n\u003cp\u003eCoronary computed tomography angiography (CCTA) is a special type of CT scan that uses intravenous contrast dye to visualize the coronary arteries in detail. Unlike a standard calcium scan, CCTA can distinguish between different types of plaque, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-calcified plaque (NCP):\u003c\/strong\u003e Soft, fatty buildup that has not yet hardened\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCalcified plaque:\u003c\/strong\u003e Older, hardened plaque containing calcium\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMixed plaque:\u003c\/strong\u003e A combination of both soft and calcified components\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe most recent American College of Cardiology\/American Heart Association (ACC\/AHA) guidelines for chest pain assessment have highlighted coronary CTA as one of the first-line tests to evaluate obstructive coronary artery stenosis (narrowing of the arteries). Regardless of how severe the narrowing appears, the overall plaque burden has been linked to poor prognosis in multiple previous reports.\u003c\/p\u003e\n\u003cp\u003eOne of the most valuable features of CCTA is its ability to identify \u003cstrong\u003ehigh-risk plaque (HRP)\u003c\/strong\u003e—features that suggest a plaque is vulnerable to rupturing. High-risk plaque features include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePositive remodeling (PR):\u003c\/strong\u003e The artery wall expands outward to accommodate plaque, which paradoxically makes the vessel look normal on the outside while harboring dangerous plaque inside\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNapkin-ring lesions:\u003c\/strong\u003e A ring-like pattern of higher density surrounding a low-density core, resembling a napkin ring\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSpotty calcification:\u003c\/strong\u003e Scattered small calcium deposits (less than 3 mm in all directions) within a partially calcified plaque\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-attenuation non-calcified plaque (LAP):\u003c\/strong\u003e Very soft plaque measuring less than 30 Hounsfield units (HU)—a measure of tissue density on CT scans\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 id=\"what-is-ncp\"\u003eWhat Is Non-Calcified Plaque?\u003c\/h2\u003e\n\u003cp\u003eNon-calcified plaque (NCP) is the earliest visible form of coronary atherosclerosis—the disease process that leads to heart attacks. It consists of lipids (fats), inflammatory cells, and connective tissue that accumulate within the artery wall. Because it is soft and fragile, NCP is more prone to rupture than calcified plaque, and a ruptured plaque can trigger a blood clot that blocks blood flow, causing a heart attack (myocardial infarction).\u003c\/p\u003e\n\u003cp\u003eThe review's central conclusion is that NCP is the initial precursor of calcified plaque. In other words, every calcified plaque was once a non-calcified plaque. This makes NCP a prominent marker of early coronary atherosclerosis and a critical target for early detection and intervention.\u003c\/p\u003e\n\u003cp\u003eFor example, consider the data from the ROMICAT-II trial, one of the key studies analyzed in this review. Patients with significant coronary artery disease (defined as at least 50% stenosis, or narrowing, in a coronary artery) were \u003cstrong\u003e34 times more likely\u003c\/strong\u003e to experience an acute coronary syndrome (ACS)—a sudden reduction of blood flow to the heart—during their hospitalization compared to those without significant CAD. When specific high-risk plaque features were examined separately, the relative risks were striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePositive remodeling: relative risk (RR) of 11.1\u003c\/li\u003e\n  \u003cli\u003eLow HU plaque (napkin-ring sign): RR of 8.2\u003c\/li\u003e\n  \u003cli\u003eSpotty calcification: RR of 37.2\u003c\/li\u003e\n  \u003cli\u003eAt least one high-risk plaque feature: RR of 32\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese numbers mean that patients with these plaque characteristics are many times more likely to experience a cardiac event, independent of how narrow the artery appears on a traditional angiogram.\u003c\/p\u003e\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThe research team performed a broad, comprehensive review of the current scientific literature pertaining to CCTA and non-calcified plaque in both symptomatic patients (those experiencing chest pain or other symptoms) and asymptomatic patients (those without symptoms). The review also included studies comparing plaque assessment on CT with intravascular ultrasound–virtual histology (IVUS-VH), an invasive imaging technique that uses sound waves to create detailed pictures of the artery wall from the inside.\u003c\/p\u003e\n\u003cp\u003eInitial searches were conducted on the PubMed database using a combination of relevant Medical Subject Headings (MeSH) terms and keywords such as \u003cem\u003e\"non-calcified coronary artery plaque,\" \"coronary CT angiogram,\" \"prevalence,\"\u003c\/em\u003e and \u003cem\u003e\"significance.\"\u003c\/em\u003e The search aimed to identify studies published in English without imposing limitations on publication dates.\u003c\/p\u003e\n\u003cp\u003eThe inclusion criteria were carefully defined to encompass studies that specifically investigated non-calcified coronary artery plaques as detected by CTA and that provided insights into both their prevalence and clinical relevance. The following types of studies were excluded:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eReviews (rather than original research)\u003c\/li\u003e\n  \u003cli\u003eCase reports\u003c\/li\u003e\n  \u003cli\u003eConference abstracts\u003c\/li\u003e\n  \u003cli\u003eStudies lacking essential data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOnly peer-reviewed, full-text articles were incorporated to uphold the credibility of the review.\u003c\/p\u003e\n\u003ch2 id=\"symptomatic-findings\"\u003eKey Findings: Non-Calcified Plaque in Patients with Symptoms\u003c\/h2\u003e\n\u003cp\u003eThe review identified seven major studies examining NCP in symptomatic patients, yielding remarkably consistent conclusions about the importance of this plaque type.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHausleiter and colleagues (2006)\u003c\/strong\u003e analyzed 161 patients and found non-calcified coronary plaques in 48 patients (29.8%). Among these:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e38 patients (23.6%) also had coronary calcifications\u003c\/li\u003e\n  \u003cli\u003e10 patients (6.2%) had non-calcified plaques as the \u003cem\u003esole manifestation\u003c\/em\u003e of coronary artery disease\u003c\/li\u003e\n  \u003cli\u003e53 patients (32.9%) had no coronary artery disease at all\u003c\/li\u003e\n  \u003cli\u003e60 patients (37.3%) had calcifications without non-calcified plaque\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003ePatients with non-calcified plaques exhibited higher total cholesterol, LDL (low-density lipoprotein, or \"bad\" cholesterol), and C-reactive protein (CRP, a marker of inflammation) levels, along with a trend toward increased diabetes mellitus. Most non-calcified plaques resulted in lumen narrowing of less than 50%, meaning they weren't causing significant blockages—yet they were still present and detectable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNance Jr. and colleagues (2012)\u003c\/strong\u003e evaluated 458 patients at low-to-intermediate risk for coronary artery disease presenting with chest pain. During a 13-month median follow-up period, the presence of plaque was associated with higher adverse outcomes. The hazard ratios (HR)—a statistical measure of how much more likely an event is in one group compared to another, where 1.0 means no difference—for each plaque type were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMixed plaque: HR 86.96\u003c\/li\u003e\n  \u003cli\u003eNon-calcified plaque: HR 58.06\u003c\/li\u003e\n  \u003cli\u003eCalcified plaque: HR 32.94\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll of these findings were statistically significant (p-values below 0.05). Patients with isolated non-calcified plaque had a significantly higher likelihood of adverse cardiac events at 5% (hazard ratio 151.77, p \u0026lt; 0.01)—meaning their risk of events was drastically elevated compared to patients without plaque.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLiu and colleagues (2017)\u003c\/strong\u003e performed a subgroup analysis on 260 individuals from the ROMICAT-II trial, analyzing segmental coronary plaque on CTA. Among 888 segments with plaque, 391 segments (44%) showed the presence of high-risk plaque features. Segments associated with high-risk plaque had higher total plaque volume, higher low-attenuation plaque volume, higher total plaque burden, and a higher remodeling index. The odds ratio (OR)—the odds that a particular finding is associated with an outcome—associated with low-attenuation plaque was 1.12 (95% CI 1.04–1.21), meaning that each unit increase in low-attenuation plaque volume increased the odds of adverse outcomes by 12%.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAl-Muhaidb and colleagues (2021)\u003c\/strong\u003e, in a retrospective study, explored the prevalence of non-calcified plaque in 299 patients with a coronary artery calcium score of zero (CACS = 0). The prevalence of NCP was found to be 6.4% (19 out of 299 patients). Among these patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e52.6% had no stenosis (narrowing)\u003c\/li\u003e\n  \u003cli\u003e26.3% had less than 25% stenosis\u003c\/li\u003e\n  \u003cli\u003e21% had 25–50% stenosis\u003c\/li\u003e\n  \u003cli\u003eNone had greater than 50% stenosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA strong association of NCP was noted with male sex, hypertension (high blood pressure), and smoking—with all p-values below 0.005.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eWilliams and colleagues (2020)\u003c\/strong\u003e conducted a post-hoc analysis of 1,769 patients with stable chest pain from the SCOT-HEART cohort, examining the presence of adverse plaque (positive remodeling and low-attenuation plaque) and its association with outcomes at 5 years. The findings were particularly compelling:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePrimary events (fatal and non-fatal myocardial infarction, or heart attack) were higher in the presence of low-attenuation plaque compared to other plaque types (HR: 1.6, 95% CI: 1.1–2.34, p = 0.014)\u003c\/li\u003e\n  \u003cli\u003eMore events were noted in patients with adverse plaque despite having a calcium score below 100 Agatston units, with an HR of 3.38 (CI 1.13 to 10.08, p = 0.03)\u003c\/li\u003e\n  \u003cli\u003eThe 41 patients who experienced fatal or nonfatal heart attacks at follow-up had significantly higher low-attenuation plaque burden: 7.5% (interquartile range 4.8–9.2) versus 4.1% (0–6.8) in patients without events (HR of 1.6; 95% CI = 1.1–2.3, p \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003eThe overall presence of a low-attenuation plaque burden greater than 4% increased the likelihood of major adverse cardiovascular events (MACE) by \u003cstrong\u003efive times\u003c\/strong\u003e in this population (HR, 4.65; 95% CI, 2.06–10.5; p \u0026lt; 0.001)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOsborne-Grinter and colleagues (2022)\u003c\/strong\u003e analyzed the same SCOT-HEART cohort and focused specifically on patients with a calcium score of zero, which was seen in 36% of patients (529 out of 1,769). Among these zero-calcium patients:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e14% had non-obstructive coronary artery disease\u003c\/li\u003e\n  \u003cli\u003e2% had obstructive coronary artery disease\u003c\/li\u003e\n  \u003cli\u003e2% had visually apparent adverse plaque\u003c\/li\u003e\n  \u003cli\u003e13% had a low-attenuation plaque burden greater than 4%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAt follow-up, 10% of the total reported heart attacks (4 out of 41) were found solely in the zero-calcium-score group. This is a crucial finding: a calcium score of zero provided false reassurance for these patients who subsequently had heart attacks.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eVillines and colleagues (2011)\u003c\/strong\u003e evaluated 10,037 symptomatic patients without known coronary artery disease from the CONFIRM registry and identified 51% of patients (5,128) with a calcium score of zero. In this group:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e84% had no underlying coronary artery disease\u003c\/li\u003e\n  \u003cli\u003e13% were diagnosed with non-obstructive non-calcified plaque\u003c\/li\u003e\n  \u003cli\u003e3.5% had luminal stenosis greater than 50%\u003c\/li\u003e\n  \u003cli\u003e1.4% had luminal stenosis greater than 70%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn patients diagnosed with non-calcified plaque, when more than 50% stenosis was identified (which occurred in 3.9% of cases), the risk of adverse events was significantly higher, with a hazard ratio of 5.7 (confidence interval: 2.5–13.1, p \u0026lt; 0.001). This means these patients were nearly six times more likely to experience adverse events compared to those without obstructive plaque.\u003c\/p\u003e\n\u003cp\u003eNotably, a receiver–operator characteristic (ROC) curve analysis demonstrated that there was \u003cstrong\u003eno significant additional prognostic value\u003c\/strong\u003e in incorporating the coronary artery calcium score when compared to assessing the extent of non-calcified plaque on CCTA for predicting composite endpoints. In other words, the CCTA findings alone were just as predictive as combining them with calcium scoring.\u003c\/p\u003e\n\u003ch2 id=\"asymptomatic-findings\"\u003eKey Findings: Non-Calcified Plaque in People Without Symptoms\u003c\/h2\u003e\n\u003cp\u003eThe review also examined multiple studies observing NCP prevalence in asymptomatic patients—individuals with no chest pain or other warning signs of heart disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRodriguez and colleagues (2015)\u003c\/strong\u003e examined 202 asymptomatic patients over 55 years old who were eligible for statin therapy. The study found that male sex was associated with a significantly higher total plaque index compared to women (42.06 mm² ± 9.22 versus 34.33 mm² ± 8.35; p \u0026lt; 0.001). The non-calcified plaque index was positively correlated with several risk factors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eElevated LDL levels: an increase of 0.04 mm² per mg\/dL (p = 0.02)\u003c\/li\u003e\n  \u003cli\u003eElevated systolic blood pressure: an increase of 0.80 mm² per 10 mmHg (p = 0.03)\u003c\/li\u003e\n  \u003cli\u003eDiabetes mellitus: an increase of 4.47 mm² (p = 0.03)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eNezarat and colleagues (2017)\u003c\/strong\u003e studied patients younger than 40 years old, comparing those with type II diabetes (86 patients) to age- and gender-matched non-diabetic controls (95 patients). Both calcified plaque and non-calcified plaque were elevated in diabetic patients compared to non-diabetics (19% vs. 58%; p \u0026lt; 0.001). Despite having a calcium score of zero, patients with diabetes had a higher prevalence of non-calcified plaque (46%, p \u0026lt; 0.0001). On quantitative plaque assessment, all volumes in the non-calcified plaque type were \u003cstrong\u003ethreefold higher\u003c\/strong\u003e in the presence of diabetes. This demonstrates that even young diabetic patients with no detectable calcium can have substantial soft plaque burden.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eKral and colleagues (2014)\u003c\/strong\u003e evaluated healthy patients with a family history of premature coronary artery disease using dual-source CT. A higher total plaque burden was identified in men versus women (57.8% vs. 35.8%, p \u0026lt; 0.0001). The non-calcified plaque volume constituted most of the total plaque volume—accounting for more than 70% of plaque in men and more than 80% of plaque in women. The study also found that NCP volume increased with age (p \u0026lt; 0.001) and was higher in men than women (p \u0026lt; 0.001), but as a percentage of total plaque, NCP was inversely related to age (p \u0026lt; 0.01)—meaning that younger patients' plaques are relatively softer and more vulnerable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCho and colleagues (2013)\u003c\/strong\u003e evaluated 4,491 asymptomatic patients with zero calcium scores who underwent CCTA as part of a general health evaluation. Non-calcified plaque was found in 7% of these patients (313 patients). The study revealed that age, male gender, diabetes mellitus, hypertension, and dyslipidemia (abnormal blood fats) were significantly associated with the presence of NCP (all p-values \u0026lt; 0.05). However, during follow-up of the 313 patients with NCP matched with patients without NCP, no difference in all-cause death or composite outcomes (cardiac death, heart attack, unstable angina requiring hospitalization, and revascularization) occurred after 90 days from the index CCTA in either group. This suggests that the short-term prognosis for these patients was reassuring.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eLee and colleagues (2013)\u003c\/strong\u003e assessed a cohort of 8,668 asymptomatic patients, including 6,531 with zero calcium scores, and identified non-calcified plaque in 6.75% (441 patients). During a mean follow-up of 26.4 ± 14.4 months, all cardiac events (death, acute coronary syndrome, or subsequent revascularization)—which occurred in only 0.18% of patients (12 patients)—occurred in patients with NCP who also had lower mean CT attenuation values (softer plaque) and a higher remodeling index. In other words, among all the asymptomatic patients with zero calcium scores, the few who experienced cardiac events were those whose non-calcified plaque had particularly dangerous characteristics.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eYang and colleagues\u003c\/strong\u003e conducted a retrospective, long-term follow-up study aimed at assessing the progression of coronary plaque and its influence on cardiac events among asymptomatic individuals with diabetes mellitus. In a cohort of 197 patients, with an average age of 63.1 years and 60% being male, and a median follow-up duration of 41.8 months, the study observed that:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients with a calcium score greater than 10 exhibited an increase in the volume of densely calcified coronary calcium\u003c\/li\u003e\n  \u003cli\u003ePatients with a calcium score of 10 or lower showed a more significant increase in the volume of low-attenuation (\"lipid-rich\") plaque components between successive CCTA scans\u003c\/li\u003e\n  \u003cli\u003eThe presence of a calcium score greater than 10 was an independent predictor of cardiac events\u003c\/li\u003e\n  \u003cli\u003eThe extent of plaque volume increase was associated with subsequent cardiac events\u003c\/li\u003e\n  \u003cli\u003eInterestingly, the level of coronary calcification appeared to have an \u003cem\u003einverse relationship\u003c\/em\u003e with outcomes in asymptomatic diabetic patients—meaning less calcification was paradoxically associated with worse outcomes, likely because softer plaque is more prone to rupture\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eJin and colleagues\u003c\/strong\u003e evaluated the characteristics and predictors of subclinical coronary atherosclerosis and cardiac events in 914 asymptomatic young adults. Non-calcified plaque was the most common type of plaque in these young adults and was identified in 6.9% of the population. Among the 46 subjects (5.3% of the cohort) who had subclinical coronary atherosclerosis:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e29 subjects had a calcium score of 0\u003c\/li\u003e\n  \u003cli\u003e17 subjects (42.5%) had a calcium score greater than 0\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eMultivariate analysis revealed a hazard ratio of 2.2 for subclinical coronary atherosclerosis, and non-calcified plaque accounted for 49.17% of cases. This confirms that even in young people, NCP is the predominant form of early heart disease.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eYoo and colleagues\u003c\/strong\u003e evaluated the presence of plaque, plaque characteristics, and calcium scores in 7,515 asymptomatic subjects. When comparing individuals with a calcium score of 0 to those with a low calcium score, the study observed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eNotably higher prevalence of non-calcified plaque in the low-calcium-score group: 31.5% versus 6.9% (p \u0026lt; 0.001)\u003c\/li\u003e\n  \u003cli\u003eIndependent factors predictive of significant NCP in the low-calcium-score group included diabetes mellitus, hypertension, and elevated LDL levels (all p-values \u0026lt; 0.05)\u003c\/li\u003e\n  \u003cli\u003eOver a median follow-up period of 42 months, individuals in the low-calcium-score group experienced a significantly higher rate of cardiac events compared to those in the zero-calcium-score group: 2.6% versus 0.27% (p \u0026lt; 0.001)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis demonstrates that even \"low\" calcium scores carry meaningful risk when accompanied by non-calcified plaque.\u003c\/p\u003e\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eThe findings of this comprehensive review carry several important messages for patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eA calcium score of zero does not mean your arteries are clear.\u003c\/strong\u003e Across multiple studies, between 4% and 7% of patients with zero calcium scores were found to have non-calcified plaque on CCTA. In the SCOT-HEART cohort, 10% of all heart attacks occurred in patients with zero calcium scores. This means that relying solely on a calcium score may give false reassurance, particularly in patients with symptoms or with risk factors such as diabetes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNon-calcified plaque is dangerous precisely because it is soft.\u003c\/strong\u003e The studies consistently showed that low-attenuation (very soft) plaque and positive remodeling—both features of non-calcified or mixed plaque—were the strongest predictors of future heart attacks. As the ROMICAT-II data showed, spotty calcification carried a relative risk of 37.2, and having any high-risk plaque feature carried a relative risk of 32. This is because soft, lipid-rich plaque is more likely to rupture than hard, calcified plaque.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCCTA provides actionable information that calcium scoring alone cannot.\u003c\/strong\u003e The Villines study found that the extent of non-calcified plaque on CCTA had equivalent predictive value to combining it with calcium scoring. This supports the growing role of CCTA as a first-line imaging test for evaluating chest pain and, increasingly, for assessing cardiovascular risk in select asymptomatic patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eA \"low-risk\" calcium score may still warrant attention.\u003c\/strong\u003e The Yoo study found that even patients with low (not zero) calcium scores had a cardiac event rate of 2.6% during a median of 42 months, compared to 0.27% in the zero-calcium group. And the Williams study found that patients with adverse plaque features and calcium scores below 100 still had a hazard ratio of 3.38 for future events.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiabetes is a particularly important risk factor for NCP.\u003c\/strong\u003e The Nezarat study found that diabetic patients younger than 40 had a 46% prevalence of non-calcified plaque even with zero calcium scores, with all plaque volumes threefold higher than non-diabetics. The Yang study showed that diabetic patients with lower calcium scores had more dangerous lipid-rich plaque progression than those with higher scores.\u003c\/p\u003e\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\u003cp\u003eSeveral limitations of this review and the underlying studies should be acknowledged.\u003c\/p\u003e\n\u003cp\u003eFirst, this is a systematic review of existing literature rather than a single prospective trial. The individual studies varied in their patient populations, imaging protocols, definitions of non-calcified plaque, and lengths of follow-up, which makes direct comparisons between studies challenging.\u003c\/p\u003e\n\u003cp\u003eSecond, many of the studies were retrospective in design, including the Al-Muhaidb, Cho, Lee, and Yang studies. Retrospective studies can have selection bias and unmeasured confounding factors.\u003c\/p\u003e\n\u003cp\u003eThird, the review included studies with relatively short follow-up durations in some cases. For example, the Cho study followed patients for only 90 days after their index CCTA, which may not be long enough to capture cardiac events that take years to develop.\u003c\/p\u003e\n\u003cp\u003eFourth, the review excluded non-English-language studies, case reports, conference abstracts, and gray literature, which could introduce publication bias.\u003c\/p\u003e\n\u003cp\u003eFifth, CCTA itself has limitations. It involves radiation exposure and intravenous contrast dye, which carries risks including allergic reactions and kidney injury in susceptible patients. Additionally, while modern CCTA has high accuracy, it can still miss very small plaques or provide suboptimal image quality in patients with fast heart rates or irregular rhythms.\u003c\/p\u003e\n\u003cp\u003eFinally, while the presence of non-calcified plaque strongly predicts cardiovascular risk, the review cannot establish that screening for NCP in asymptomatic patients improves long-term outcomes. Randomized controlled trials of CCTA-guided management strategies are needed to confirm this benefit.\u003c\/p\u003e\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on the findings of this review and current guidelines, here are actionable recommendations for patients:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have chest pain or other cardiac symptoms, ask about CCTA.\u003c\/strong\u003e The ACC\/AHA guidelines now recommend coronary CTA as a first-line test for evaluating obstructive coronary artery disease in patients with chest pain. CCTA can detect both narrowings \u003cem\u003eand\u003c\/em\u003e plaque characteristics that predict risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not assume a calcium score of zero means no heart disease.\u003c\/strong\u003e If you have symptoms, multiple risk factors, or a strong family history of premature heart disease, ask your doctor whether a CCTA would provide additional information beyond a calcium score.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have diabetes, be especially vigilant.\u003c\/strong\u003e The data show that diabetic patients, even young ones with zero calcium scores, can harbor substantial non-calcified plaque. Aggressive risk factor management is critical.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAddress modifiable risk factors identified in these studies.\u003c\/strong\u003e The studies consistently linked high LDL cholesterol, high blood pressure, smoking, and diabetes to the presence and progression of non-calcified plaque. Work with your doctor to control these factors through lifestyle changes and medications such as statins.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand the concept of \"vulnerable plaque.\"\u003c\/strong\u003e Not all plaque is created equal. If your CCTA report mentions high-risk features such as positive remodeling, low-attenuation plaque, napkin-ring lesions, or spotty calcification, these findings warrant serious attention and aggressive medical therapy—even if the blockages themselves are not severe.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStatic imaging is a snapshot, not a final verdict.\u003c\/strong\u003e Plaque is dynamic. With appropriate treatment—particularly statin therapy, blood pressure control, and lifestyle modification—plaque can stabilize or even regress. Early detection of non-calcified plaque creates an opportunity to alter the disease's evolutionary course, potentially preventing future heart attacks.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThe review's authors emphasize that by detecting non-calcified plaque during early stages, several medical measures can be implemented that can alter the trajectory of the underlying disease. This can potentially lead to a lower incidence of major adverse cardiovascular events.\u003c\/p\u003e\n\u003cp\u003eIf you have concerns about your heart disease risk, particularly if you have symptoms, diabetes, or a family history of early heart disease, ask your healthcare provider whether a CCTA might provide a more complete picture of your cardiovascular health than a calcium score alone.\u003c\/p\u003e\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is non-calcified plaque?\u003c\/h3\u003e\n\u003cp\u003eNon-calcified plaque is soft, fatty buildup inside coronary artery walls. It is the earliest visible form of atherosclerosis and can rupture, triggering heart attacks. Unlike calcified plaque, it is invisible on standard calcium-scoring CT scans, but coronary CT angiography with contrast dye can detect it.\u003c\/p\u003e\n\u003ch3\u003eWhat is CCTA and how is it different from a calcium score?\u003c\/h3\u003e\n\u003cp\u003eCCTA is a CT scan using intravenous contrast dye to see coronary arteries in detail. It can distinguish non-calcified, calcified, and mixed plaque. A standard calcium score only detects calcified plaque, which appears later. CCTA can show soft, dangerous plaque that calcium scoring misses.\u003c\/p\u003e\n\u003ch3\u003eIf my calcium score is zero, does that mean I have no heart disease?\u003c\/h3\u003e\n\u003cp\u003eNo. Studies show between 4% and 7% of patients with zero calcium scores still have non-calcified plaque on CCTA. In one large study, 10% of all heart attacks occurred in patients with zero calcium scores. A zero calcium score can give false reassurance, especially with symptoms or diabetes.\u003c\/p\u003e\n\u003ch3\u003eWhat are high-risk plaque features on CCTA?\u003c\/h3\u003e\n\u003cp\u003eHigh-risk plaque features include positive remodeling (artery wall expands outward), napkin-ring lesions, spotty calcification, and low-attenuation non-calcified plaque. These features make plaque vulnerable to rupturing. In one trial, having any high-risk feature carried a relative risk of 32 for acute coronary syndrome.\u003c\/p\u003e\n\u003ch3\u003eHow much more likely are heart attacks with non-calcified plaque?\u003c\/h3\u003e\n\u003cp\u003eRisk varies by plaque characteristics. In studies, hazard ratios ranged from 1.6 to over 151. For example, in one study, patients with non-calcified plaque had a hazard ratio of 58 for adverse events, while those with high-risk features had relative risks up to 37 for spotty calcification.\u003c\/p\u003e\n\u003ch3\u003eI have diabetes. Should I be especially concerned about non-calcified plaque?\u003c\/h3\u003e\n\u003cp\u003eYes. One study found diabetic patients under 40 had 46% prevalence of non-calcified plaque even with zero calcium scores, with plaque volumes threefold higher than non-diabetics. Another study showed diabetic patients with low calcium scores had more dangerous lipid-rich plaque progression. Diabetes is a major risk factor for soft plaque.\u003c\/p\u003e\n\u003ch3\u003eWhat should I do if I have chest pain or high risk factors?\u003c\/h3\u003e\n\u003cp\u003eAsk your doctor about CCTA. Current guidelines recommend it as a first-line test for chest pain evaluation. If you have diabetes, multiple risk factors, or a family history of early heart disease, CCTA may provide more information than a calcium score alone. Address LDL, blood pressure, smoking, and diabetes with your healthcare team.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003eThis patient-friendly article is based on the following peer-reviewed research publication:\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal Title:\u003c\/strong\u003e Non-Calcified Coronary Artery Plaque on Coronary Computed Tomography Angiogram: Prevalence and Significance\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Bandar Alyami, Matthew Santer, Karthik Seetharam, Dhivya Velu, Eswar Gadde, Bansari Patel, and Yasmin S. Hamirani\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Tomography, 2023, Volume 9, Pages 1755–1771\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3390\/tomography9050140\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Date:\u003c\/strong\u003e September 20, 2023\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eType of Article:\u003c\/strong\u003e Systematic review\u003c\/p\u003e\n\u003cp\u003eThis article was published under the Creative Commons Attribution (CC BY) license and may be freely shared and adapted with appropriate citation. The patient-friendly summary above maintains all numerical data, statistical findings, and conclusions from the original source while translating technical terminology into accessible language for patients and their families.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47457936048284,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.cn\/products\/non-calcified-coronary-artery-plaque-on-ct-angiograms-what-it-is-how-common-it-is-and-why-it-matters-for-your-heart","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}